Status:
UNKNOWN
Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions:
Coronavirus Disease 2019
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is estimating the predictive and preventative capability of thrombodynamics for severe pneumonia coagulopathy complications in patients with COVID-19 infection. Thrombodynamics te...
Detailed Description
The novel coronavirus viral infection (currently classified as COVID-19) causes a significant increase in death rate worldwide. Most of the patients with COVID-19 develop respiratory failure as well a...
Eligibility Criteria
Inclusion
- Patient (or the health care surrogate) Informed consent
- Confirmed COVID-19 diagnosis
Exclusion
- 1\) Patient (or the health care surrogate) refusal to participate in this study
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 21 2022
Estimated Enrollment :
2200 Patients enrolled
Trial Details
Trial ID
NCT05330832
Start Date
April 1 2020
End Date
April 21 2022
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dmitry Rogachev National Medical Research Centre of Pediatric Hematology, Oncology and Immunology
Moscow, Russia